2019
Screening for HBV, HCV, HIV and syphilis infections among bacteriologically confirmed tuberculosis prisoners: An urgent action required
Puga M, Bandeira L, Pompilio M, de Rezende G, Soares L, de Castro V, Tanaka T, Cesar G, de Oliveira S, Teles S, Yassuda R, dos Santos Weis-Torres S, Basílio S, Croda J, Motta-Castro A. Screening for HBV, HCV, HIV and syphilis infections among bacteriologically confirmed tuberculosis prisoners: An urgent action required. PLOS ONE 2019, 14: e0221265. PMID: 31437184, PMCID: PMC6705821, DOI: 10.1371/journal.pone.0221265.Peer-Reviewed Original ResearchConceptsHepatitis B virusSyphilis infectionViral hepatitisHIV infectionB virusAnti-HCV positive samplesChronic hepatitis B virusFirst-line anti-tuberculosis drugsLifetime syphilis infectionCases of tuberculosisAnti-TB drugsCross-sectional studyPublic health problemAnti-tuberculosis drugsCurrent HCVHCV exposureHCV RNAHepatitis testingTuberculosis infectionActive syphilisSerological markersEpidemiological featuresFrequent causeSide effectsHCV
2016
Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil
Heinrich M, Zembrzuski V, Ota M, Sacchi F, Teixeira R, Acero P, Cunha G, Souza-Santos R, Croda J, Basta P. Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil. Tuberculosis 2016, 101: 15-24. PMID: 27865386, DOI: 10.1016/j.tube.2016.07.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntitubercular AgentsArylamine N-AcetyltransferaseBrazilChemical and Drug Induced Liver InjuryChildChild, PreschoolCross-Sectional StudiesCytochrome P-450 CYP2E1FemaleGenetic Predisposition to DiseaseGenotypeGlutathione TransferaseHumansIncidenceInfantLongitudinal StudiesMaleMiddle AgedPolymorphism, Single NucleotideTuberculosis, PulmonaryYoung AdultConceptsIncidence of hepatotoxicityAdverse drug reactionsIndigenous patientsAnti-TB drug-induced hepatotoxicityNon-conditional logistic regressionClinical-epidemiological factorsClinical-epidemiological variablesNon-Indigenous patientsGenetic polymorphismsRisk of hepatotoxicityDrug-induced hepatotoxicityPolymorphisms of CYP2E1Anti-tuberculosis drugsAcetylation profileTB patientsSerum levelsDrug reactionsGSTM1 polymorphismOdds ratioLiver enzymesNon-Indigenous populationsTherapeutic schemesPharmacogenetic analysisBetter outcomesPatients